MedTrace Logo

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

NCT01021540 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2011-07-14

No results posted yet for this study

Summary

To determine if H.P. Acthar Gel (repository corticotrophin) has the same anti-proteinuric effects seen with the synthetic ACTH analogue in Europe.

Conditions

  • Nephrotic Syndromes

Interventions

DRUG

Repository corticotrophin

Acthar 80 IU SQ once a week and titrated up to twice a week

Sponsors & Collaborators

  • Arizona Kidney Disease and Hypertension Center

    lead OTHER

Principal Investigators

  • Sungchun Lee, M.D. · Arizona Kidney Disease and Hypertension Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01021540 on ClinicalTrials.gov